Zacks Research Upgrades Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) to Hold

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) was upgraded by stock analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a research report issued on Monday,Zacks.com reports.

A number of other equities analysts have also issued reports on FMS. Citigroup reissued a “neutral” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research report on Friday, April 24th. Weiss Ratings lowered shares of Fresenius Medical Care AG & Co. KGaA from a “hold (c+)” rating to a “hold (c)” rating in a research note on Thursday, May 7th. Morgan Stanley reissued an “underweight” rating on shares of Fresenius Medical Care AG & Co. KGaA in a report on Wednesday, May 6th. Jefferies Financial Group raised shares of Fresenius Medical Care AG & Co. KGaA from a “strong sell” rating to a “moderate sell” rating in a report on Friday, May 8th. Finally, Wall Street Zen lowered Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “hold” rating in a research note on Saturday, May 9th. Five investment analysts have rated the stock with a Hold rating and four have issued a Sell rating to the company. According to MarketBeat, the company has an average rating of “Reduce” and an average price target of $28.00.

Fresenius Medical Care AG & Co. KGaA Price Performance

NYSE FMS opened at $24.20 on Monday. The company has a market cap of $13.00 billion, a price-to-earnings ratio of 12.73, a PEG ratio of 4.26 and a beta of 0.78. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.20 and a quick ratio of 0.86. The stock’s fifty day moving average price is $22.38 and its 200 day moving average price is $22.84. Fresenius Medical Care AG & Co. KGaA has a 1 year low of $20.02 and a 1 year high of $27.76.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last posted its quarterly earnings results on Tuesday, March 31st. The company reported $1.05 earnings per share for the quarter. Fresenius Medical Care AG & Co. KGaA had a return on equity of 8.90% and a net margin of 4.88%.The business had revenue of $5.34 billion for the quarter. As a group, equities research analysts forecast that Fresenius Medical Care AG & Co. KGaA will post 2.24 earnings per share for the current year.

Hedge Funds Weigh In On Fresenius Medical Care AG & Co. KGaA

Hedge funds have recently bought and sold shares of the business. Moran Wealth Management LLC increased its holdings in Fresenius Medical Care AG & Co. KGaA by 31.5% in the 1st quarter. Moran Wealth Management LLC now owns 347,773 shares of the company’s stock worth $7,846,000 after acquiring an additional 83,311 shares in the last quarter. Pzena Investment Management LLC grew its position in shares of Fresenius Medical Care AG & Co. KGaA by 2.0% in the first quarter. Pzena Investment Management LLC now owns 15,052,822 shares of the company’s stock valued at $339,592,000 after purchasing an additional 299,986 shares during the period. ABC Arbitrage SA grew its position in shares of Fresenius Medical Care AG & Co. KGaA by 1,136.0% in the fourth quarter. ABC Arbitrage SA now owns 249,800 shares of the company’s stock valued at $5,950,000 after purchasing an additional 229,589 shares during the period. Ritholtz Wealth Management increased its stake in shares of Fresenius Medical Care AG & Co. KGaA by 252.7% during the first quarter. Ritholtz Wealth Management now owns 84,658 shares of the company’s stock worth $1,910,000 after purchasing an additional 60,652 shares in the last quarter. Finally, XY Capital Ltd purchased a new stake in shares of Fresenius Medical Care AG & Co. KGaA during the third quarter worth about $978,000. Hedge funds and other institutional investors own 8.37% of the company’s stock.

About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG & Co KGaA is the world’s largest integrated provider of products and services for individuals with renal diseases. The company’s primary business activities encompass the operation of dialysis clinics and the manufacture and distribution of dialysis equipment, dialysis machines, dialyzers, consumables and related therapies. Through its global network of clinics, Fresenius Medical Care delivers comprehensive kidney care, including hemodialysis and peritoneal dialysis treatments, patient education and support services.

In its products segment, the company designs and produces dialysis machines, water treatment systems and disposables such as high‐flux dialyzers and bloodlines.